Hemangioma: Types, Appearance, and Treatment

What hemangiomas actually are and how they differ from other vascular marks

Hemangiomas are benign vascular tumors composed of proliferating endothelial cells that form abnormal clusters of blood vessels. Unlike vascular malformations, which represent structural errors in vessel formation present from birth, hemangiomas are true neoplasms that undergo distinct phases of growth and regression. The term "hemangioma" encompasses several distinct entities, each with unique clinical behavior and prognosis.

The most common type is the infantile hemangioma, which typically appears within the first few weeks of life. These lesions are absent or minimally visible at birth, then enter a rapid proliferative phase during the first months of life. This growth period is followed by a slow involution phase that can last several years. By contrast, congenital hemangiomas are fully developed at birth and do not undergo the same proliferative phase. These subtypes are distinguished by their behavior, not their appearance at birth, which can make early classification difficult.

How hemangiomas connect to systemic biology

The development of infantile hemangiomas involves complex interactions between angiogenic factors, hypoxia signaling, and endothelial cell proliferation. During the proliferative phase, elevated levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) drive rapid vessel formation. Hypoxia-inducible factors activate when tissue oxygen levels drop, triggering a cascade that promotes new blood vessel growth.

The involution phase involves a shift toward apoptosis of endothelial cells and replacement of vascular tissue with fibrous and fatty tissue. This process is mediated by decreased angiogenic signaling and increased expression of factors that promote cell death and tissue remodeling. The mechanisms underlying spontaneous regression remain incompletely understood but appear to involve both intrinsic cellular programming and changes in the local tissue environment.

Hormonal influences may play a role in hemangioma development and behavior. The higher incidence in females and the occasional observation of accelerated growth during puberty suggest estrogen sensitivity in some cases. Premature infants show increased risk, possibly related to incomplete vascular development or altered growth factor expression in the extrauterine environment.

Systemic factors can influence hemangioma behavior beyond local tissue dynamics. Thyroid dysfunction has been associated with certain hemangioma presentations, particularly in cases of multiple lesions. Cardiovascular stress from large or multiple hemangiomas can occasionally lead to high-output cardiac failure in infants, as the low-resistance vascular beds within these tumors shunt significant blood volume.

What determines whether a hemangioma needs treatment

Most hemangiomas do not require intervention. The natural history of infantile hemangiomas favors involution, and the majority resolve with minimal residual change. But certain features elevate the risk of complications and warrant early treatment.

Location and functional risk

Hemangiomas near the eyes can obstruct vision during critical periods of visual development, potentially causing permanent amblyopia. Periorbital lesions that distort the visual axis or prevent eyelid opening require prompt treatment to preserve normal vision. Airway hemangiomas, particularly those in the subglottic region, can compromise breathing and necessitate urgent intervention. Lesions near the ear canal may interfere with hearing development.

Ulceration

Surface breakdown occurs in approximately 10% of infantile hemangiomas, most commonly in areas subject to friction or moisture. Ulceration causes pain, bleeding, and infection risk. The resulting wounds heal slowly and increase the likelihood of permanent scarring. Early treatment can help manage ulceration in high-risk locations or accelerate healing once it occurs.

Size and growth rate

Large hemangiomas (greater than 5 cm) and those demonstrating rapid proliferation during the first months of life carry higher risk of complications and residual deformity. Extensive facial lesions may cause significant disfigurement during critical periods of social development. Segmental hemangiomas, which cover a broad anatomic territory, are more likely to ulcerate and less likely to involute completely compared to focal lesions.

Associated syndromes

Large facial hemangiomas may occur as part of PHACE syndrome (posterior fossa malformations, hemangiomas, arterial anomalies, cardiac defects, eye abnormalities). Multiple cutaneous hemangiomas can indicate visceral involvement, particularly hepatic hemangiomas that may cause complications. Recognition of these patterns prompts evaluation for associated structural anomalies.

Why the same diagnosis can look and behave differently

Not all infantile hemangiomas follow the textbook trajectory. Some grow minimally and involute early. Others proliferate aggressively and leave significant residual tissue. The reasons for this variability are not fully understood, but several factors contribute.

Depth and composition

Superficial hemangiomas appear as bright red, raised lesions with a characteristic strawberry appearance. Deep hemangiomas present as bluish subcutaneous masses with less distinct borders. Mixed lesions contain both superficial and deep components. Deeper lesions tend to proliferate longer and involute more slowly, often leaving residual fibrofatty tissue even after complete regression of the vascular component.

Timing of appearance and growth

Hemangiomas that appear earlier and grow more rapidly during the first weeks of life tend to reach larger size overall. The duration of the proliferative phase varies, typically lasting 3 to 6 months but sometimes extending beyond the first year. Earlier cessation of growth generally predicts more complete involution and less residual change.

Genetic and hormonal factors

Familial clustering suggests genetic predisposition in some cases, though specific inheritance patterns remain unclear. Glucose transporter 1 (GLUT1) expression distinguishes infantile hemangiomas from other vascular tumors and may relate to their unique growth characteristics. Hormonal influences during infancy, when growth hormone and other developmental signals are active, may modulate proliferation and involution rates.

Congenital hemangioma subtypes

Rapidly involuting congenital hemangiomas (RICH) regress completely within the first year of life, often leaving minimal residual change. Non-involuting congenital hemangiomas (NICH) remain stable in size throughout life and do not undergo spontaneous regression. Partially involuting congenital hemangiomas (PICH) show incomplete regression, stabilizing with residual tissue. These distinct behaviors reflect fundamental differences in cellular programming despite similar appearance at birth.

When skin symptoms point to something systemic

A single small hemangioma is rarely a cause for concern beyond its local effects. But certain presentations warrant a broader evaluation.

Five or more cutaneous hemangiomas raise suspicion for hepatic involvement. Liver hemangiomas can be asymptomatic or cause complications including high-output cardiac failure, hypothyroidism from excessive type 3 iodothyronine deiodinase activity, or consumptive coagulopathy. Abdominal imaging is indicated when multiple skin lesions are present.

Large segmental facial hemangiomas, particularly those involving the lower face and neck, should prompt evaluation for PHACE syndrome. Associated anomalies include posterior fossa brain malformations, cerebrovascular abnormalities, aortic coarctation and other cardiac defects, and eye abnormalities. Brain and cardiac imaging, along with ophthalmologic examination, help identify these potentially serious associated conditions.

Lumbosacral hemangiomas may signal underlying spinal dysraphism or tethered cord. The acronym LUMBAR (lower body hemangioma and other cutaneous defects, urogenital anomalies, ulceration, myelopathy, bony deformities, anorectal malformations, arterial anomalies, and renal anomalies) describes this association. Spinal imaging is warranted for hemangiomas in this location, particularly when accompanied by other midline cutaneous markers.

What testing and monitoring can reveal

Most hemangiomas are diagnosed clinically, based on appearance and behavior. Imaging is reserved for cases where the diagnosis is uncertain, the lesion is deep or extensive, or there is concern for associated anomalies. Ultrasound with Doppler can confirm the vascular nature of a lesion and distinguish hemangiomas from other soft tissue masses. High-flow characteristics and specific architectural patterns support the diagnosis.

Magnetic resonance imaging (MRI) provides detailed anatomic information for deep or complex lesions. MRI can delineate the extent of involvement, assess proximity to critical structures, and identify associated anomalies in syndromic cases. For suspected PHACE syndrome, brain MRI and magnetic resonance angiography of the head and neck vessels are standard. Cardiac evaluation includes echocardiography to assess for structural defects and aortic arch anomalies.

Biopsy is rarely needed but may be performed if the diagnosis is uncertain or if the lesion does not respond to treatment as expected. Histologic examination can confirm the diagnosis and rule out other vascular tumors or malignancies.

How treatment decisions are made

The decision to treat a hemangioma is based on its potential to cause harm, not its presence alone. Active observation is appropriate for most lesions. When treatment is indicated, the goal is to halt proliferation, accelerate involution, or manage complications.

Propranolol, a non-selective beta-blocker, has become first-line therapy for problematic infantile hemangiomas. The mechanism involves vasoconstriction of existing vessels, decreased expression of angiogenic factors including VEGF and bFGF, and induction of apoptosis in proliferating endothelial cells. Treatment typically begins during the proliferative phase and continues for several months to a year. Response is often dramatic, with visible reduction in size and color within weeks.

Topical beta-blockers (timolol gel) offer an alternative for small, superficial lesions where systemic therapy is not warranted. The medication penetrates the skin to exert local effects on the hemangioma without significant systemic absorption. This approach avoids the cardiovascular and metabolic effects of oral propranolol while still providing benefit for appropriate lesions.

Corticosteroids, once the mainstay of treatment, are now used less frequently given the superior efficacy and safety profile of propranolol. Steroids reduce hemangioma growth through anti-angiogenic and anti-inflammatory mechanisms. They remain an option when beta-blockers are contraindicated or in resource-limited settings.

Laser therapy targets the vascular component of hemangiomas using wavelengths selectively absorbed by hemoglobin. Pulsed dye laser is most commonly used for superficial lesions and can reduce redness, manage ulceration, or treat residual telangiectasias after involution. Laser does not effectively treat deep components and is not a substitute for systemic therapy in high-risk cases. For port-wine stains (capillary malformations often confused with hemangiomas), laser represents the primary treatment modality, as these lesions do not involute spontaneously.

If your child has a hemangioma that's growing rapidly, located near the eyes or airway, or causing pain or bleeding, working with a pediatric dermatologist or vascular anomalies specialist is essential for timely intervention. For adults with persistent vascular lesions or concerns about associated conditions, tracking inflammatory markers, thyroid function, and cardiovascular risk factors provides a clearer picture of overall health beyond the skin.